Gr-1+ cells and the response to nematode parasites

Gr-1 细胞和对线虫寄生虫的反应

基本信息

项目摘要

DESCRIPTION (provided by applicant): T helper 2 (Th2) effector cells, through Th2 cytokine production, can mediate resistance to helminthic parasite infection. Understanding the cell and molecular interactions that lead to their differentiation is therefore important for the development of therapies and vaccines that promote host protective immune responses. We have begun to examine the innate response that initially develops following infection of mice with nematode parasites to identify cell populations or signals that may be important in promoting adaptive immunity that leads to the developing of IL-4 producing Th2 cells. Global gene expression analyses of draining lymph nodes shortly after parasite infection showed pronounced increases in chemokines, including MCP-1 and CXCR3 ligands. Both chemokines are known to recruit monocytes and granulocytes. Gr-1 is a cell surface marker shared by these cell populations and also plasmacytoid dendritic cells. Draining lymph nodes showed pronounced increases in Gr1+ cells at 4 and 16 hours after inoculation with the intestinal nematode parasite, N. brasiliensis. Treatment with anti-GR-1 antibody caused marked increases in lymph node IFN-y expression at 18 hours after N. brasiliensis inoculation and decreased IL-4 expression and host resistance was observed at 7 days after inoculation. In the proposed studies, we will examine the function of Gr1+ cells in promoting the development of Th2 effector cells in vivo. Specifically, we propose to identify the chemokine/chemokine receptors that mediate the recruitment of Gr1+ cells to the peripheral lymph nodes at early stages of the immune response to N. brasiliensis. We will also elucidate the mechanism of how Gr1+ cells suppress IFN-y elevations and promote Th2 cell development leading to host resistance by examining Gr1+ cell interactions with developing Th2 cells in situ. Finally, we will address in two parasite models, N. brasiliensis and H. polygyrus, the role of Gr1+ cells in the development of the host protective primary and memory response.
描述(由申请人提供):辅助性T细胞2(Th 2)效应细胞,通过Th 2细胞因子的产生,可以介导对蠕虫寄生虫感染的抗性。因此,了解导致其分化的细胞和分子相互作用对于开发促进宿主保护性免疫反应的疗法和疫苗非常重要。我们已经开始检查小鼠感染线虫寄生虫后最初产生的先天性反应,以鉴定可能在促进导致产生IL-4的Th 2细胞的适应性免疫中重要的细胞群或信号。寄生虫感染后不久引流淋巴结的全球基因表达分析显示趋化因子显著增加,包括MCP-1和CXCR 3配体。已知这两种趋化因子都募集单核细胞和粒细胞。Gr-1是这些细胞群以及浆细胞样树突状细胞共有的细胞表面标志物。引流淋巴结在接种肠道线虫寄生虫N.巴西的。用抗GR-1抗体处理引起N.接种后7 d,IL-4的表达量和寄主抗性均下降。在本研究中,我们将研究Gr 1+细胞在体内促进Th 2效应细胞发育的功能。具体来说,我们建议确定趋化因子/趋化因子受体介导的招聘Gr 1+细胞的外周淋巴结在早期阶段的免疫反应,以N。巴西的。我们还将阐明Gr 1+细胞如何抑制IFN-γ的升高,促进Th 2细胞的发展,从而导致宿主抗性的机制,通过检查Gr 1+细胞与发展中的Th 2细胞在原位的相互作用。最后,我们将在两个寄生虫模型,N。brasiliensis和H. polygyrus,Gr 1+细胞在宿主保护性初级和记忆反应的发展中的作用。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

William Clark Gause其他文献

William Clark Gause的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('William Clark Gause', 18)}}的其他基金

The role of pathogen-experienced macrophage subsets in mediating lung immunity and heterologous protection
经历病原体的巨噬细胞亚群在介导肺免疫和异源保护中的作用
  • 批准号:
    10753773
  • 财政年份:
    2023
  • 资助金额:
    $ 37.75万
  • 项目类别:
Protective and pathologic functions of macrophages induced by helminths
蠕虫诱导的巨噬细胞的保护和病理功能
  • 批准号:
    10062803
  • 财政年份:
    2017
  • 资助金额:
    $ 37.75万
  • 项目类别:
Induction of effector lymphocyte lethargy by helminth coinfection
蠕虫共感染诱导效应淋巴细胞昏睡
  • 批准号:
    9403748
  • 财政年份:
    2017
  • 资助金额:
    $ 37.75万
  • 项目类别:
Protective and pathologic functions of macrophages induced by helminths
蠕虫诱导的巨噬细胞的保护和病理功能
  • 批准号:
    10312027
  • 财政年份:
    2017
  • 资助金额:
    $ 37.75万
  • 项目类别:
Induction of effector lymphocyte lethargy by helminth coinfection
蠕虫共感染诱导效应淋巴细胞昏睡
  • 批准号:
    9917695
  • 财政年份:
    2017
  • 资助金额:
    $ 37.75万
  • 项目类别:
Genesis of Defective Effector Lymphocytes in the Helminth-Coinfected Host
蠕虫共感染宿主中缺陷效应淋巴细胞的起源
  • 批准号:
    9330361
  • 财政年份:
    2016
  • 资助金额:
    $ 37.75万
  • 项目类别:
Innate type 2 immune mechanisms of resistance
先天2型免疫抵抗机制
  • 批准号:
    8573312
  • 财政年份:
    2013
  • 资助金额:
    $ 37.75万
  • 项目类别:
Innate type 2 immune mechanisms of resistance
先天2型免疫抵抗机制
  • 批准号:
    8708756
  • 财政年份:
    2013
  • 资助金额:
    $ 37.75万
  • 项目类别:
Gr-1+ cells and the response to nematode parasites
Gr-1 细胞和对线虫寄生虫的反应
  • 批准号:
    7373545
  • 财政年份:
    2006
  • 资助金额:
    $ 37.75万
  • 项目类别:
Gr-1+ cells and the response to nematode parasites
Gr-1 细胞和对线虫寄生虫的反应
  • 批准号:
    7762243
  • 财政年份:
    2006
  • 资助金额:
    $ 37.75万
  • 项目类别:

相似海外基金

Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
  • 批准号:
    23K08213
  • 财政年份:
    2023
  • 资助金额:
    $ 37.75万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
  • 批准号:
    2881726
  • 财政年份:
    2023
  • 资助金额:
    $ 37.75万
  • 项目类别:
    Studentship
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
  • 批准号:
    10735090
  • 财政年份:
    2023
  • 资助金额:
    $ 37.75万
  • 项目类别:
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
  • 批准号:
    10722146
  • 财政年份:
    2023
  • 资助金额:
    $ 37.75万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 37.75万
  • 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
  • 批准号:
    10935776
  • 财政年份:
    2023
  • 资助金额:
    $ 37.75万
  • 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
  • 批准号:
    10935796
  • 财政年份:
    2023
  • 资助金额:
    $ 37.75万
  • 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
  • 批准号:
    10935775
  • 财政年份:
    2023
  • 资助金额:
    $ 37.75万
  • 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
  • 批准号:
    10735964
  • 财政年份:
    2023
  • 资助金额:
    $ 37.75万
  • 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
  • 批准号:
    10649041
  • 财政年份:
    2023
  • 资助金额:
    $ 37.75万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了